Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4570 results about "Pharmaceutical formulation" patented technology

Pharmaceutical formulation, in pharmaceutics, is the process in which different chemical substances, including the active drug, are combined to produce a final medicinal product. The word formulation is often used in a way that includes dosage form.

Compositions and methods of use for modified release minoxidil

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.
Owner:VERADERMICS INC

Crystal form of resmetirom, and preparation method therefor and use thereof

PCT designated stage expiredWO2025011259A1Organic active ingredientsOrganic chemistryAgonist drugsPharmaceutical drug
The present invention relates to a new crystal form of Resmetirom and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a THR-β selective agonist pharmaceutical formulation and a pharmaceutical formulation for treating MASH and HeFH.
Owner:CRYSTAL PHARMA CO LTD

New crystal form of rosemeltirol and preparation method thereof

The invention provides a novel crystal form and a novel crystal form APTI-I. The novel crystal form and the novel crystal form APTI-I are radiated by Cu-K alpha, and an X-ray powder diffraction pattern represented by a 2 theta angle has characteristic peaks at 5.0 degrees + / -0.2 degrees, 6.3 degrees + / -0.2 degrees, 7.8 degrees + / -0.2 degrees, 12.2 degrees + / -0.2 degrees and 20.0 degrees + / -0.2 degrees. The crystal form is easy to prepare, high in purity, good in stability and good in solubility in a water solvent, and is suitable for industrial large-scale production and preparation of pharmaceutical preparations.
Owner:AURISCO PHARM(TIANJIN) INC

Pharmaceutical formulations of an amylin receptor agonist and a GLP-1 receptor agonist comprising a cyclodextrin

Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.
Owner:NOVO NORDISK AS

Pharmaceutical formulations for the treatment of migraine

ActiveUS12310953B2Organic active ingredientsNervous disorderHepatic impairmentMigraine
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.
Owner:MERCK SHARP & DOHME LLC

Protein nanoparticle for treating ulcerative colitis as well as preparation method and application thereof

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.
Owner:CHINA PHARM UNIV

Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine

PendingUS20250281412A1Organic active ingredientsAntiviralsEmtricitabineTenofovir alafenamide
The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
Owner:GILEAD SCIENCES INC

Pharmaceutical composition containing mirogabalin

PCT designated stage expiredWO2024248079A1Organic active ingredientsNervous disorderMirogabalinPharmacy medicine
The present invention addresses the problem of providing a solid preparation that contains a high-quality mirogabalin besylate and has excellent storage stability. The solution of the present invention is a pharmaceutical solid preparation that contains mirogabalin besylate and does not substantially contain a reducing sugar.
Owner:DAIICHI SANKYO CO LTD

Rimetirol 1, 4-dioxane solvent compound and preparation method thereof

The invention provides a solvent compound crystal which is formed by rosmeltirol and a 1, 4-dioxane solvent, and the molecular formula of the solvent compound crystal is C17H12Cl2N6O4.C4H8O2. The preparation process of the crystal form is simple, the operation is simple and convenient, the quality index of the obtained crystal form is basically kept unchanged in a stability acceleration experiment, the crystal form has good stability and is easy to store in the production circulation process, a good choice is provided for preparation of a medicinal preparation of the crystal form, and the crystal form has very important significance for medicine development.
Owner:HANGZHOU CHEMINSPIRE TECH CO LTD

Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation

A packaged, sealed container system for stable storage of a formulation of an oxygen-sensitive pharmaceutical compound, the packaged, sealed container system comprising a primary container including therein a formulation of an oxygen-sensitive pharmaceutical compound, a secondary outer container comprising a first flexible sheet layer, an opposing second flexible sheet layer, and a seal disposed along a common peripheral edge of the first and second flexible sheet layers, such that the primary container is disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. An oxygen scavenger is also disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. The oxygen scavenger is in fluid communication with the contents of the primary container.
Owner:BAXTER INT INC +1

Anti-CD137 antigen-binding molecule and utilization thereof

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.
Owner:CHUGAI PHARMA CO LTD

Preparation method and application of exosome vesicles capable of efficiently loading drugs

The invention relates to the technical field of exosome loaded drugs, and provides a preparation method and application of exosome vesicles capable of efficiently loading drugs, and the preparation method comprises the following steps: exosome preparation: preparing an exosome sample with enough granularity and purity; pretreatment of exosomes: performing precipitation treatment and collecting the exosomes to prepare exosome precipitates; carrying out loaded medicine pretreatment: treating loaded medicine or a medicine preparation by using a lipid reagent; target drug loading: rapidly treating the exosome precipitate by using a drug lipid component, and then treating by using a buffer system to obtain the exosome load of the drug; and free lipid and drug removal: reducing free lipid and drug residues by re-enriching the exosomes. The problems of high concentration, high purity and low cost in industrial production of the exosome are solved, meanwhile, an efficient and convenient technical method is provided for taking the exosome loaded medicine as a delivery system, and the method can be suitable for the fields of health medical treatment, medical beauty cosmetics and biological medicine products.
Owner:BAIYANHUI (SHENZHEN) DOCTOR GRP CO LTD

Extended release pharmaceutical formulation

The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
Owner:DOUGLAS PHARMA

Lipids for nanoparticle delivery platform

The present disclosure includes ionizable lipids suitable for lipid nanoparticle compositions and pharmaceutical formulations thereof. The lipids have general formula (I).
Owner:JANSSEN PHARMA NV

Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
Owner:ESSENTIALIS INC

A kind of beclomethasone dipropionate suspension for inhalation and preparation method thereof

The present invention relates to the technical field of pharmaceutical preparations, and specifically discloses a beclomethasone dipropionate suspension for inhalation and a preparation method thereof. The present invention uses polyethylene glycol hyaluronic acid as a surfactant, polysorbate 80 (II) as a wetting agent, and colloidal microcrystalline cellulose as a suspending agent, first prepares an auxiliary material solution containing part of the surfactant, the wetting agent and the suspending agent, and a drug solution of beclomethasone dipropionate and the surfactant, and then mixes the drug solution with the auxiliary material solution and homogenizes under high pressure to prepare the beclomethasone dipropionate suspension for inhalation. The prepared beclomethasone dipropionate suspension has excellent storage stability and effective lung deposition rate, effectively solves the potential harm to respiratory tissue caused by the use of a large amount of Tween 20 and Span-type surfactants in the original research, can achieve a good replacement for the original research product, and has a simple preparation process, good repeatability, and is easy to achieve industrialized large-scale production, and has a high value of promotion and application.
Owner:HEBEI CHUANGJIAN PHARMA +2

Long-acting sustained-release pharmaceutical preparation and preparation method therefor

A long-acting sustained-release pharmaceutical preparation and a preparation method therefor. The long-acting sustained-release pharmaceutical preparation is a microsphere preparation, which comprises brexpiprazole and PLGA, wherein the content of brexpiprazole is 45%-75% of the total weight of the microsphere, the content of PLGA is 55%-25% of the total weight of the microsphere, and PLGA has a viscosity of 0.15-0.25 dl / g and a molecular weight of 8000-32000. The microsphere has a relatively high drug loading capacity, can effectively reduce the administration dosage and reduce the pain in patients during subcutaneous or intramuscular administration; and the prepared sustained-release microsphere has no burst release phenomenon, and has a stable change in blood drug concentration within an effective period of release in rats.
Owner:WUHAN WUYAO SCI & TECH CO LTD

Ionizable lipid compound, lipid nanoparticle containing same, pharmaceutical composition, pharmaceutical preparation and application thereof

Provided are an ionizable lipid compound, a lipid nanoparticle comprising the same, a pharmaceutical composition, a pharmaceutical formulation, and uses thereof. Specifically, the invention provides an ionizable lipid compound, and an N-oxide, a pharmaceutically acceptable salt, a prodrug or a stereoisomer thereof. The structure of the compound is as follows: # imgabs0 # R1 is C2-10 alkylene; r2 is a C2-10 alkylene group or-CH2CH2-N (CH2CH2OH)-CnH2n-, and n is an integer from 2 to 10; l1 and L2 are-O (C = O)-,-(C = O) O-,-NH (C = O)-or-(C = O) NH-; r3 is phenyl substituted by oxygen alkyl, wherein the oxygen alkyl is C2-20 oxygen alkyl; r4 is C2-25 alkyl or phenyl substituted by oxyalkyl, wherein the oxyalkyl is C2-20 oxyalkyl; and R5 is a C2-6 alkylene group. A delivery system containing the compound is low in toxicity and high in delivery efficiency, and the in-vivo expression of the medicine is continuous and stable.
Owner:NAT VACCINE & SERUM INST

A liquid pharmaceutical formulation of clonidine hydrochloride

The present invention is a liquid pharmaceutical formulation of clonidine hydrochloride. The present invention also a liquid pharmaceutical formulation of clonidine hydrochloride comprising clonidine hydrochloride, preservative, sweetener and a suitable vehicle, wherein the formulation is free of buffer. The present invention also a liquid pharmaceutical formulation of clonidine hydrochloride and process of preparing the same.
Owner:NOVUMGEN LTD

Systems for treating pulmonary infections

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.
Owner:INSMED INC